RxDoctor Payments Data

Julio Vieira, MD

Neurology · Kingston, NYNPI 1962776138

Payments from drug & device makers

$147,470in general payments, 2019–2025

Across 358 payments — averaging $411.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$116K
  • Biohaven Pharmaceutical Holding Company Ltd.$9K
  • Pfizer$7K
  • Axsome Therapeutics, Inc.$7K
  • Biodelivery Sciences International, Inc.$3K
  • Amneal Pharmaceuticals LLC$2K
  • plus $3K from 11 others
$5,410in research payments, 2019–2025

Across 4 payments — averaging $1352.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$5K

What the payments were for

  • Consulting fees$13,0169%
  • Speaking & faculty fees$117,79080%
  • Travel & lodging$5,9524%
  • Food & beverage$10,6747%
  • Education$380%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$147,470 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$207,952
Medicare patients
245
Services billed
12,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate108$217,855
UbrelvyUbrogepant103$155,594
Emgality PenGalcanezumab-Gnlm87$69,696
QuliptaAtogepant14$18,190
Ajovy AutoinjectorFremanezumab-Vfrm17$16,279
Ajovy SyringeFremanezumab-Vfrm15$10,252
Donepezil Hcl43$2,424
Propranolol Hcl ErPropranolol Hcl35$1,602
Gabapentin74$1,571
Tizanidine Hcl73$1,354
RizatriptanRizatriptan Benzoate77$1,035
Sumatriptan Succinate78$946
Topiramate82$900
Pregabalin26$823
Levetiracetam32$812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$7,134$217,855108 claims
AbbVieUbrelvy, Qulipta$116,459$173,784117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.

Other neurology in Kingston

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →